The Swiss biotech company Memo Therapeutics AG closes a series A financing round of 2.3 million Swiss Francs to develop and validate its MemoMAB™ antibody discovery platform

Series A financing round

Memo Therapeutics AG today announced the successful completion of its series A financing round of 2.3 million Swiss Francs which has been raised from Swiss investors (including EVA Basel, Redalpine Venture Partners and Zürcher Kantonalbank). The funds will be used to develop and validate its MemoMAB™ antibody discovery platform. MemoMAB™ will be used for discovery of novel human-derived antibodies and of antibodies against difficult targets from animals.

 

Press release (e).